Navigation Links
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Date:10/22/2008

tory arrest, catastrophic brain damage and death.

In the treatment of hyponatremia associated with congestive heart failure, Vaprisol is indicated only for those patients for whom the expected benefit of raising serum sodium outweighs the increased risk of adverse events. Vaprisol is contraindicated in patients with hypovolemic hyponatremia.

About Hyponatremia

Hyponatremia, a condition of low serum sodium concentration, often results from elevated levels of the hormone arginine vasopressin (AVP), which regulates water and salt balance in the body. It is the most common electrolyte disorder in clinical medicine and one of the most difficult to treat. Syndrome of inappropriate antidiuretic hormone (SIADH), advanced kidney failure, hypothyroidism and cancer are common causes of hyponatremia. Dilutional hyponatremia, which includes euvolemic and hypervolemic hyponatremia, is the most common form of the condition, and occurs when retained water dilutes serum sodium content. Patients with hyponatremia are classified as hypervolemic if swelling of body tissues (edema) is present or euvolemic if there is an increase in total body water content without edema.

About Vaprisol

Discovered and developed by Astellas Pharma Inc. headquartered in Tokyo, Japan, Vaprisol is a drug that blocks the activity of AVP, resulting in increased urine output without loss of valuable electrolytes such as sodium and potassium. This effect, known as "aquaresis," helps to increase serum sodium levels in patients with hyponatremia. Vaprisol is the first AVP receptor antagonist with a demonstrated safety profile and that effectively promotes aquaresis in order to help restore salt and water balance in patients with euvolemic and hypervolemic hyponatremia.

Vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used fo
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
2. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
3. FDA Approves Fougeras Clotrimazole Cream USP 1%
4. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
5. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
6. Signalife Board Approves Merger
7. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
8. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
9. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
10. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
11. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... , August 3, 2015 ... Study on 3D Cell Culture: Asia ... Persistence Market Research, the global 3D cell culture market was valued ... to expand at a CAGR of 29.1% to account ... Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D ...
(Date:7/31/2015)... , July 31, 2015 In today,s ... that help them drive positive health outcomes, improve ... source of patient care in their communities. At ... tradeshow and conference, AmerisourceBergen announced a new set ... Services Administration Organization and help independent pharmacies endure ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... alarming pace, a University of Central Florida research team is ... a miniature diagnostic toolkit in the hopes of stimulating earlier ... the National Science Foundation for up to $600,000 over three ... of a credit card to detect damaging levels of oxygen ...
... Protection Agency today outlined a new research strategy ... human health and the environment. Nanomaterials are materials ... A nanometer is approximately 1/100,000 the width of ... in hundreds of consumer products, including sunscreen, cosmetics ...
... ... new ClearTrial TRACK provides integrated planning, outsourcing, project tracking, reforecasting, accrual management, and ... ... www.cleartrial.com ), the leading provider of Clinical Trial Operations (CTO) software, announced today ...
Cached Biology Technology:UCF team developing tool kit to help diagnose dementia 2EPA announces research strategy to study nanomaterials 2ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 2ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 3ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 4
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... the human mind in the hope of answering some ... to the nature of knowledge. Today cognitive scientists link ... research in various areas, an approach epitomized by WIREs ... The content of this journal will be free for ...
... Iowa - Research at Iowa State University has led scientists ... and eventually kills them. A research team led by Gaya ... had previously solved the structure of a critical part of ... host immune suppression. Amarasinghe and his research team now know ...
... GAINESVILLE, Fla. The University of Florida,s Institute on ... National Institutes of Health to construct an almost 40,000-square-foot ... building will bring together scientists from a range of ... out on the campus. "This is a unique ...
Cached Biology News:Iowa State University researcher discovers Ebola's deadly secret 2UF gets almost $15 million in federal funds to build research complex to help older adults 2UF gets almost $15 million in federal funds to build research complex to help older adults 3
...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... mixed TAMRA isomers are predominantly used for ... preferred for labeling peptides and nucleotides because ... that is often required in the conjugation ... 6-TAMRA for labeling peptides and proteins. 6-TAMRA ...
Biology Products: